Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
36
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Is this overpriced ASX share too much of a gamble?
stocks
ASX players that might thrive under a Trump administration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,269.63 | 42.17 | -0.58% |
| DAX 40 | 19,210.81 | 52.89 | -0.27% |
| Dow JONES (US) | 43,444.99 | 305.87 | -0.70% |
| FTSE 100 | 8,063.61 | 7.58 | -0.09% |
| HKSE | 19,426.34 | 9.47 | -0.05% |
| NASDAQ | 18,680.12 | 427.53 | -2.24% |
| Nikkei 225 | 38,642.91 | 107.21 | 0.28% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,870.62 | 78.55 | -1.32% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,330.73 | 49.11 | -1.45% |